Companies › ACADIA Pharmaceuticals
3 active drug programs in 7 registered trials: 3 Phase 2, 2 Phase 3, 2 Phase 4; Neurology, Psychiatry, Metabolic and endocrine, Other; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ACP-204 5-HT2A receptor antagonist/inverse agonist | HTR2A | Phase 3 | Lewy Body Dementia Psychosis; Alzheimer's Disease Psychosis | Jan 2028 |
| Carbetocin (ACP-101) Oxytocin receptor agonist | OXTR | Phase 3 | Hyperphagia in Prader-Willi Syndrome; Postpartum Hemorrhage | – |
| ACP-211 Muscarinic M1 receptor positive allosteric modulator | CHRM1 | Phase 2 | Major Depressive Disorder (MDD) | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06173531 | Carbetocin (ACP-101) | Phase 3 | Hyperphagia in Prader-Willi Syndrome | Metabolic and endocrine | Aug 2025 |
| NCT07284667 | ACP-211 | Phase 2 | Major Depressive Disorder (MDD) | Psychiatry | Aug 2027 |
| NCT06159673 | ACP-204 | Phase 2 | Alzheimer's Disease Psychosis | Neurology | Jan 2028 |
| NCT07029581 | ACP-204 | Phase 2 | Lewy Body Dementia Psychosis | Neurology | Feb 2028 |
| NCT07401524 | Carbetocin (ACP-101) | Phase 4 | Postpartum Hemorrhage | Other | Mar 2028 |
| NCT07636421 | Carbetocin (ACP-101) | Phase 4 | Postpartum Hemorrhage | Other | Apr 2028 |
| NCT07095465 | ACP-204 | Phase 3 | Lewy Body Dementia Psychosis | Neurology | Feb 2029 |
Cash and short-term investments of $976m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Alkermes PTC Therapeutics Neurocrine Biosciences Idorsia Pharmaceuticals Supernus Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.